

## **AMENDMENTS TO THE CLAIMS**

This Listing of Claims will replace all prior versions, and listings, of all claims in the application.

### **Listing of Claims:**

1-55. (Canceled).

56. (Currently Amended) A pharmaceutical composition comprising:

a) a therapeutically effective amount of an ACE inhibitor;

b) a therapeutically effective amount of ~~and of~~ a BMP morphogen selected from the group consisting of OP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-15, Vgr-1, DPP, 60A, Vg1, CBMP2A, CBMP2B, GDF-1, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, MP121, DORSALIN, UNIVIN, NODAL, SCREW, ADMP and NURAL; and

~~c), formulated with~~ a pharmaceutically acceptable salt, carrier, excipient or diluent[[],];

wherein the combination of said ACE inhibitor and BMP morphogen is capable of

synergistically inducing a synergistic effect on reducing proteinuria levels in a patient having diabetic nephropathy model.

57-68. (Canceled).

69. (Previously Presented) The pharmaceutical composition of claim 56, wherein the ACE inhibitor is Enalapril.

70. (Currently Amended) The pharmaceutical composition of claim 56, wherein the BMP morphogen is the polypeptide of SEQ ID NO: 3.

71. **(Currently Amended)** The pharmaceutical composition of claim 56, wherein the BMP morphogen is ~~a first polypeptide including at least a C-terminal cysteine domain of a protein selected from: a pro form, a mature form, or a soluble form of a second polypeptide, wherein said second polypeptide is~~ selected from: OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, or BMP9,  
wherein said BMP morphogen comprises at least the C-terminal cysteine domain.

72-75. **(Canceled).**

76. **(Currently Amended)** The pharmaceutical composition of claim 56, wherein said ACE inhibitor ACEI is selected from the group consisting of: ~~any one compound of the formulas I-XXVIII or their salts thereof; acylmercapto and mercaptoalkanoyl prolines; captopril (1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline); ether or thioether mercaptoacyl prolines; zofenopril; carboxyalkyl dipeptides; enalapril (N-(1-ethoxycarbonyl-3-phenylpropyl)-L-ananyl-L-proline); lisinopril; quinapril; ramipril; carboxyalkyl dipeptide mimics; cilazapril; benazapril; phosphinylalkanoyl prolines; fosinopril;trandolopril; phosphonamide substituted amino or imino acids; phosphonate substituted amino or imino acids and salts thereof; ceronapril ((S)-1-[6-amino-2-[[hydroxyl(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline); BRL 36,378; MC-838; CGS 14824 (3-([1-ethoxycarbonyl-3-phenyl-(1S)-propyl]-amino)-2,3,4,5-tetrahydro-2-oxo-1-(3S)-benzazepine-1 acetic acid HCL); CGS 16,617 (3(S)-[[ (1S)-5-amino-1-carboxypentyl]amino]2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid); Cetapril (alacepril, Dainippon); Ru 44570; Cilazapril; Ro 31-2201; Lisinopril; Indalapril (delapril); Rentiapril (fentiapril, Santen); Indolapril; Spirapril; Perindopril; Quinapril; CI 925 ([3S-[2[R(\*)R(\*)]3R(\*)]-2-[2-[1-(ethoxy-carbonyl)-3-~~

phenylpropyl]amino[-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-  
isoquinolinecarboxylic acid HCL); WY-44221; ~~mercapto-containing compounds~~; pivopril;  
YS980; Omapatrilat; Alacepril; moveltopril; quinaprilat; moexipril; perinodpril (S-9490);  
pentopril; ancovenin; phenacein; and ~~or~~ nicotianamin.

77. **(Canceled).**

78. **(Currently Amended)** A packaged pharmaceutical comprising the pharmaceutical composition of claim 56, 69-71 or 76, in association with instructions for administering the composition to a mammal for treatment or prevention of chronic renal failure.